Congenital generalised lipodystrophy type 2 is a serious multisystem disorder with limited treatment options. It is caused by mutations affecting the BSCL2 gene, which encodes the protein seipin. Patients with congenital generalised lipodystrophy type 2 lack both metabolic and mechanical adipose tissue and develop severe metabolic complications including hepatic steatosis, lipoatrophic diabetes and cardiovascular disease. Gene therapies are becoming viable treatments, helping to alleviate inherited and acquired human disorders. We aimed to determine whether gene therapy could offer an effective form of medical intervention for lipodystrophy. We examined whether systemic adeno-associated virus delivery of human BSCL2 could reverse metabolic disease in seipin knockout mice, where white adipose tissue is absent. We reveal adeno-associated virus gene therapy targets adipose progenitor cells in vivo and substantially restores white adipose tissue development in adult seipin knockout mice. This resulted in both rapid and prolonged beneficial effects to metabolic health in this pre-clinical mouse model of congenital generalised lipodystrophy type 2. Hyperglycaemia was normalised within two weeks post-treatment, together with normalisation of severe insulin resistance. We propose that gene therapy offers great potential as a therapeutic strategy to correct multiple metabolic complications in patients with congenital lipodystrophy.
|Number of pages||11|
|Journal||Molecular Therapy - Methods & Clinical Development|
|Early online date||19 Oct 2022|
|Publication status||Published - 8 Dec 2022|
FingerprintDive into the research topics of 'Gene therapy restores adipose tissue and metabolic health in a pre-clinical mouse model of lipodystrophy'. Together they form a unique fingerprint.
Microscopy and Histology
Debbie Wilkinson (Manager) & Gillian Milne (Manager)Medical Sciences
Research Facilities: Facility